Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $28.94

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month […]

Related Keywords

United States , Stifel Nicolaus , Markc Schneyer , Brendan Teehan , Pharmaceuticals Price Performance , Shell Asset Management Co , Securities Exchange Commission , Jpmorgan Chase Co , Citigroup , Pharmaceuticals Daily , Nasdaq , Pharmaceuticals Inc , Quest Partners , Covestor Ltd , Headlands Technologies , Get Free Report , Exchange Commission , Management Fondsmaeglerselskab , Shell Asset Management , Asset Management , Get Free ,